Cabume - Cambridge technology news | Babraham antibodies spin-out lands £17.5m funding round Cabume - Cambridge technology news A diagram of a regular antibody structure and the crescendo version Crescendo Biologics, a Cambridge biotech firm with a platform for the production of the tiniest of human antibody fragments suitable for use in drug discovery, has sealed a £17.5 ... Crescendo Biologics raises $28 million Imperial Innovations Group plc : Innovations leads £17.5m funding round for ... Imperial spearheads $28M round for an upstart in the antibody fragment field |
